ALK-Abelló, the Makers of GRAZAX(R), Present Successful Phase III Clinical Study Results with Children
Horsholm, Denmark (ots/PRNewswire) - - Results Show Highly Significant Effect on Rhinoconjunctivitis (Hay Fever) and Asthma Symptoms in Children from age 5 to 16 Years-old ALK-Abelló yesterday presented successful Phase III clinical study results with GRAZAX(R) in children at the American Academy ...